Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Therapeutic applications of transcription factor decoy oligonucleotides
Michael J. Mann, Victor J. Dzau
Michael J. Mann, Victor J. Dzau
Published November 1, 2000
Citation Information: J Clin Invest. 2000;106(9):1071-1075. https://doi.org/10.1172/JCI11459.
View: Text | PDF
Perspective

Therapeutic applications of transcription factor decoy oligonucleotides

  • Text
  • PDF
Abstract

Authors

Michael J. Mann, Victor J. Dzau

×

Figure 2

Options: View larger image (or click on image) Download as PowerPoint
Vein grafts are initially thin-walled vessels that must undergo wall thi...
Vein grafts are initially thin-walled vessels that must undergo wall thickening to resist increased stress in the arterial circulation. The neointimal hyperplasia that produces this thickening, however, involves the proliferation of activated smooth muscle cells that create a substrate for accelerated atherosclerosis and subsequent graft occlusion. Blocking neointimal hyperplasia, as we have done using an E2F decoy oligonucleotide, induces an adaptive hypertrophic thickening of the medial layer of the vessel, yielding hemodynamic stability without increased susceptibility to atherosclerotic disease.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts